drug

TAK-360

Phase 2updated 3mo ago

by $TAK TAKEDA PHARMACEUTICAL CO LTD

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying TAK-360

phase2A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)recruitingn=88
phase3A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomniarecruitingn=500
phase2A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)recruitingn=92
phase2A Study of TAK-360 in Adults With Idiopathic Hypersomniarecruitingn=96

News(1)

Takeda leads wave of orexin drugs with potential to upend narcolepsy market
The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
biospace · 2d ago

Data sources

ClinicalTrials.gov

last refreshed 34m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

TAK-360

Phase 2updated 3mo ago

by $TAK TAKEDA PHARMACEUTICAL CO LTD

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying TAK-360

phase2A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)recruitingn=88
phase3A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomniarecruitingn=500
phase2A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)recruitingn=92
phase2A Study of TAK-360 in Adults With Idiopathic Hypersomniarecruitingn=96

News(1)

Takeda leads wave of orexin drugs with potential to upend narcolepsy market
The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
biospace · 2d ago

Data sources

ClinicalTrials.gov

last refreshed 34m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

TAK-360

all catalysts(0)

Trials studying TAK-360

News(1)

Report a data issue

comments(0)

TAK-360

all catalysts(0)

Trials studying TAK-360

News(1)

Report a data issue

comments(0)